SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
HuMAB companies
An SI Board Since May 2000
Posts SubjectMarks Bans
1022 55 0
Emcee:  nigel bates Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
972MorphoSys Announces Clinical Milestone from Strategic Alliance August 02, 2010 Germanecki-8/4/2010
971MorphoSys AG Reports Six Months 2010 Results July 28, 2010 / 07:00 Full Year GGermanecki-8/4/2010
970MorphoSys Announces Clinical Milestone from Strategic Alliance July 01, 2010 / Germanecki-7/2/2010
969MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical AntibGermanecki-7/2/2010
968MorphoSys Announces Clinical Milestone June 22, 2010 / 08:30 <b>First ofGermanecki-6/24/2010
967UPDATE 1-Genmab CEO quits Danish biotech under fire reuters.com * Departure foA.J. Mullen-6/18/2010
966GHENT, Belgium, 24 May 2010 –Ablynx today announced that Boehringer Ingelheim hanigel bates-5/26/2010
965S.A. patients helping test novel bone building therapy for multiple myeloma keGermanecki-5/1/2010
964MorphoSys AG Reports Results for the First Quarter of 2010 April 27, 2010 / 08:Germanecki-5/1/2010
963GHENT, Belgium, 26 March 2010 - Ablynx [Euronext Brussels: ABLX] announced todaynigel bates-3/29/2010
962MorphoSys Granted Further Patent on its Core Antibody Technology in Japan MARTINGermanecki-3/15/2010
961MorphoSys and Galapagos Expand Antibody Alliance 02/18/2010 at 07:30 AM MorphoGermanecki-2/18/2010
960Interesting read for those interested in Ablynx: ncbi.nlm.nih.govnigel bates-2/9/2010
959Thanks Dew. I was surprised by the soft treatment given presenters the first tiA.J. Mullen-2/2/2010
958<i>>Are European analysts harder-nosed than Americans<</i> BDewDiligence_on_SI-2/2/2010
957I became interested in Genmab given its pronounced sell-off. I put it into my cA.J. Mullen-2/1/2010
956Arzerra (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europtnsaf-1/25/2010
955MorphoSys Enrolls First Patient in Phase 1b/2a Clinical Trial for MOR103 ProgramGermanecki-1/19/2010
954MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MGermanecki-11/9/2009
953GHENT, Belgium, 12 October, 2009 - Ablynx [Euronext Brussels: ABLX], today annonigel bates-10/28/2009
952>>Glaxo filed a lawsuit Oct. 8<< LONDON, Oct 8 (Reuters) - GlaxoSminigel bates-10/27/2009
951<b>Genmab Surges After FDA Clears Cancer Drug Shared With Glaxo</b> idos-10/27/2009
950HGSI finally announces some PIII results for their lupus mAB: Message 26032716 nigel bates-10/20/2009
949MorphoSys and Daiichi Sankyo Forge Alliance to Develop Novel Antibody Therapies Germanecki-10/20/2009
948Roche plans to start P2-Study in Alzheimer desease efkabe.de RG1450 is a fullyGermanecki-10/15/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News